The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en

被引:84
作者
Blick, TJ
Sahasrabudhe, A
McDonald, M
Owens, IJ
Morley, PJ
Fenton, RJ
McKimm-Breschkin, JL
机构
[1] Biomol Res Inst, Parkville, Vic 3052, Australia
[2] Glaxo Wellcome Res & Dev Ltd, Stevenage SG1 2NY, Herts, England
关键词
D O I
10.1006/viro.1998.9194
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have previously described a 4-guanidino-Neu5Ac2en (zanamivir)-resistant neuraminidase (NA) variant G70C4-G, with an active site mutation Glu 119 to Gly. This variant has been found to also harbor a hemagglutinin (HA) mutation in the receptor binding site, Ser 186 to Phe. Examination of early passages of the G70C4-G virus revealed that this HA mutation had arisen by the first passage. From a subsequent passage two transient variants were isolated which had each acquired a different second HA mutation, Ser 165 to Asn and Lys 222 to Thr. Both were highly drug resistant and drug dependent and their ability to adsorb to and penetrate cells was decreased. Comparison of drug sensitivities between the variant, with the additional HA mutation at Ser 165, and viruses with either mutation alone revealed that these two HA mutations acted synergistically to increase resistance. To determine the contribution to resistance of each of the NA and HA mutations in G70C4-G, the NA mutation was separated from the HA mutation by reasserting. The NA mutation and the HA mutation each conferred low-level resistance to zanamivir, while the two mutations interacted synergistically in the double mutant to give higher resistance in vitro. Infectivity was not adversely affected in the double mutant and while there was a small decrease in sensitivity to zanamivir in the mouse model, there was no detectable resistance to zanamivir in the ferret model. (C) 1998 Academic Press.
引用
收藏
页码:95 / 103
页数:9
相关论文
共 32 条
[1]   Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en [J].
Blick, TJ ;
Tiong, T ;
Sahasrabudhe, A ;
Varghese, JN ;
Colman, PM ;
Hart, GJ ;
Bethell, RC ;
McKimmBreschkin, JL .
VIROLOGY, 1995, 214 (02) :475-484
[2]   COOPERATIVE EFFECTS BETWEEN 2 ACYCLOVIR RESISTANCE LOCI IN HERPES-SIMPLEX VIRUS [J].
DARBY, G ;
CHURCHER, MJ ;
LARDER, BA .
JOURNAL OF VIROLOGY, 1984, 50 (03) :838-846
[3]   Binding of the influenza A virus to cell-surface receptors: Structures of five hemagglutinin-sialyloligosaccharide complexes determined by x-ray crystallography [J].
Eisen, MB ;
Sabesan, S ;
Skehel, JJ ;
Wiley, DC .
VIROLOGY, 1997, 232 (01) :19-31
[4]  
Gottschalk A, 1959, VIRUSES, P51
[5]   Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en [J].
Gubareva, LV ;
Robinson, MJ ;
Bethell, RC ;
Webster, RG .
JOURNAL OF VIROLOGY, 1997, 71 (05) :3385-3390
[6]   Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en [J].
Gubareva, LV ;
Bethell, R ;
Hart, GJ ;
Murti, KG ;
Penn, CR ;
Webster, RG .
JOURNAL OF VIROLOGY, 1996, 70 (03) :1818-1827
[7]   The bacterial outer membrane as a drug barrier [J].
Hancock, REW .
TRENDS IN MICROBIOLOGY, 1997, 5 (01) :37-42
[8]   Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza [J].
Hayden, FG ;
Treanor, JJ ;
Betts, RF ;
Lobo, M ;
Esinhart, JD ;
Hussey, EK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (04) :295-299
[9]   BIOGENESIS OF MITOCHONDRIA 34 - SYNERGISTIC INTERACTION OF NUCLEAR AND MITOCHONDRIAL MUTATIONS TO PRODUCE RESISTANCE TO HIGH LEVELS OF MIKAMYCIN IN SACCHAROMYCES-CEREVISIAE [J].
HOWELL, N ;
MOLLOY, PL ;
LINNANE, AW ;
LUKINS, HB .
MOLECULAR & GENERAL GENETICS, 1974, 128 (01) :43-54
[10]   MUTAGENIC STUDY OF CODON-74 AND CODON-215 OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE, WHICH ARE SIGNIFICANT IN NUCLEOSIDE ANALOG RESISTANCE [J].
LACEY, SF ;
LARDER, BA .
JOURNAL OF VIROLOGY, 1994, 68 (05) :3421-3424